Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Citoplurikin; IRX-2

Latest Information Update: 16 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IRX Therapeutics
  • Developer Brooklyn ImmunoTherapeutics; Providence Health & Services; University of Southern California
  • Class Antineoplastics; Cytokines
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cervical intraepithelial neoplasia; Head and neck cancer; Vulvar intraepithelial neoplasia
  • Phase I Breast cancer

Most Recent Events

  • 04 Dec 2018 Efficacy and adverse events data from a phase Ib trial in Breast cancer presented at the at the 41st Annual San Antonio Breast Cancer Symposium (SABCS- 2018)
  • 29 Nov 2018 H. Lee Moffitt Cancer Center and Research Institute plans a phase I trial for Solid tumours (Recurrent; Late-stage disease; Second-line therapy or greater) in USA, (NCT03758781)
  • 07 Nov 2018 IRX Therapeutics has been acquired and merged into Brooklyn ImmunoTherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top